Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (592)	11/14/2001 7:02:26 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

While they confirmed good safety and pharmacology profile for IL-1 Trap, no words on drug activity at multiple doses (6 + 4 weeks) in RA pts. Strange? <<``We're delighted with the results we have seen so far with the IL-1 Trap,'' commented Dr. Hans-Peter Guler, Regeneron's Vice President, Clinical Sciences. ``These findings are completely consistent with the results predicted in preclinical studies. Based on these preliminary results, we're eager to move as rapidly as we can into Phase II studies.'' >> I am eager to read or hear about drug activity in PIb (surrogate markers and/or ACR activity). Kineret is no match for Embrel. Miljenko